NEW YORK (GenomeWeb News) — Shimadzu and Waters plan to co-develop software that will allow Waters’ Empower chromatography software to control Shimadzu’s Prominence liquid chromatographer.
Shimadzu said the collaboration is a response to the need of pharmaceutical clients to be able to integrate data from multiple chromatographs from various makers on a single data system.
Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.